AG真人官方

STOCK TITAN
  1. Home
  2. News
  3. VTVT
  4. vTv Therapeutics to Participate in the H.C. Wainwright 鈥淗CW@Home鈥� Series

vTv Therapeutics to Participate in the H.C. Wainwright 鈥淗CW@Home鈥� Series

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
vTv Therapeutics (VTVT) announced its participation in the virtual H.C. Wainwright 'HCW@Home' Series on June 12, 2025. The company, which focuses on developing cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for type 1 diabetes treatment, will participate in a fireside chat at 10:00 AM ET. Key company executives including Paul Sekhri (Chairman, President & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO), and Michael Tung (CFO) will engage in the discussion moderated by Emily Bodnar from H.C. Wainwright. The event will be accessible via webcast on the company's website.
vTv Therapeutics (VTVT) ha annunciato la sua partecipazione alla serie virtuale 'HCW@Home' di H.C. Wainwright il 12 giugno 2025. L'azienda, specializzata nello sviluppo di cadisegliatin, una potenziale terapia orale adjunctiva di prima classe per il trattamento del diabete di tipo 1, prender脿 parte a una conversazione informale alle 10:00 ET. I principali dirigenti dell'azienda, tra cui Paul Sekhri (Presidente, CEO e Chairman), Thomas Strack (CMO), Carmen Valcarce (CSO) e Michael Tung (CFO), parteciperanno alla discussione moderata da Emily Bodnar di H.C. Wainwright. L'evento sar脿 accessibile tramite webcast sul sito web dell'azienda.
vTv Therapeutics (VTVT) anunci贸 su participaci贸n en la serie virtual 'HCW@Home' de H.C. Wainwright el 12 de junio de 2025. La compa帽铆a, que se centra en el desarrollo de cadisegliatin, una posible terapia oral adyuvante de primera clase para el tratamiento de la diabetes tipo 1, participar谩 en una charla informal a las 10:00 AM ET. Ejecutivos clave de la empresa, incluidos Paul Sekhri (Presidente, CEO y Presidente del Consejo), Thomas Strack (CMO), Carmen Valcarce (CSO) y Michael Tung (CFO), participar谩n en la discusi贸n moderada por Emily Bodnar de H.C. Wainwright. El evento ser谩 accesible v铆a webcast en el sitio web de la compa帽铆a.
vTv Therapeutics(VTVT)電� 2025雲� 6鞗� 12鞚� H.C. Wainwright鞚� 臧�靸� 鞁滊Μ歃� 'HCW@Home'鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 鞚� 須岇偓電� 1順� 雼闺嚚氤� 旃橂毳� 鞙勴暅 斓滌磮鞚� 瓴疥惮 氤挫“ 鞖旊矔 頉勲炒鞚� cadisegliatin 臧滊皽鞐� 欤茧牓頃橁碃 鞛堨溂氅�, 鞓れ爠 10鞁�(霃欕秬鞁滉皠)鞐� 歆勴枆霅橂姅 韼胳晥頃� 雽�頇旍棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�. Paul Sekhri(須岇灔, 靷灔 氚� CEO), Thomas Strack(CMO), Carmen Valcarce(CSO), Michael Tung(CFO) 霌� 欤检殧 瓴届榿歆勳澊 H.C. Wainwright鞚� Emily Bodnar臧� 歆勴枆頃橂姅 韱犽鞐� 彀胳棳頃╇媹雼�. 頄夓偓電� 須岇偓 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿� 鞁滌箔頃� 靾� 鞛堨姷雼堧嫟.
vTv Therapeutics (VTVT) a annonc茅 sa participation 脿 la s茅rie virtuelle 'HCW@Home' de H.C. Wainwright le 12 juin 2025. La soci茅t茅, sp茅cialis茅e dans le d茅veloppement de cadisegliatin, une th茅rapie orale adjuvante potentielle de premi猫re classe pour le traitement du diab猫te de type 1, participera 脿 une discussion informelle 脿 10h00 ET. Les principaux dirigeants, dont Paul Sekhri (Pr茅sident, PDG et Pr茅sident du conseil), Thomas Strack (Directeur m茅dical), Carmen Valcarce (Directrice scientifique) et Michael Tung (Directeur financier), prendront part 脿 la discussion anim茅e par Emily Bodnar de H.C. Wainwright. L'茅v茅nement sera accessible en webcast sur le site internet de la soci茅t茅.
vTv Therapeutics (VTVT) gab bekannt, dass es am 12. Juni 2025 an der virtuellen H.C. Wainwright 'HCW@Home'-Reihe teilnimmt. Das Unternehmen, das sich auf die Entwicklung von Cadisegliatin konzentriert, einer potenziellen oral einzunehmenden Zusatztherapie der ersten Klasse zur Insulinbehandlung bei Typ-1-Diabetes, wird an einem Fireside-Chat um 10:00 Uhr ET teilnehmen. Wichtige F眉hrungskr盲fte des Unternehmens, darunter Paul Sekhri (Vorsitzender, Pr盲sident & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO) und Michael Tung (CFO), werden an der von Emily Bodnar von H.C. Wainwright moderierten Diskussion teilnehmen. Die Veranstaltung wird per Webcast auf der Website des Unternehmens zug盲nglich sein.
Positive
  • None.
Negative
  • None.

HIGH POINT, N.C., June 11, 2025 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc.听(Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of听cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the H.C. Wainwright 鈥淗CW@Home鈥� Series, being held virtually on听Thursday, June 12, 2025.

Conference details are as follows:

H.C. Wainwright听鈥淗CW@Home with vTv Therapeutics鈥�
Format: Fireside Chat
Moderator:听Emily Bodnar, Director, H.C. Wainwright
vTv Therapeutics Speakers:

  • Paul Sekhri, Chairman of the Board, President & Chief Executive Officer
  • Thomas Strack, MD, Chief Medical Officer
  • Carmen Valcarce, Ph.D., Executive Vice President, Chief Scientific Officer
  • Michael Tung, MD, MBA, Chief Financial Officer

Date:听Thursday, June 12, 2025
Time:听10:00 AM ET
Webcast Link: Register

The webcast of the event will be accessible from News & Events page of the听vTv听website.

About听vTv听Therapeutics
vTv Therapeutics Inc.听is a late-stage biopharmaceutical company focused on developing oral, small molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. vTv's clinical pipeline is led by听cadisegliatin, currently in a Phase 3 trial, a potential first-in-class oral glucokinase activator being investigated for the treatment of听type 1 diabetes. vTv and its development partners are investigating multiple molecules into different indications for chronic diseases. Learn more at听听or follow the company on听听or听.

Investor Contact
John Fraunces
LifeSci Advisors, LLC
917-355-2395

Media Contact
Caren Begun
TellMed Strategies
201-396-8551


FAQ

What is the purpose of vTv Therapeutics' (VTVT) participation in the H.C. Wainwright conference?

vTv Therapeutics will participate in a fireside chat discussion to present information about their company and development of cadisegliatin, their potential first-in-class oral therapy for type 1 diabetes.

When and where will the VTVT H.C. Wainwright conference presentation take place?

The virtual presentation will take place on Thursday, June 12, 2025, at 10:00 AM ET through the H.C. Wainwright 'HCW@Home' Series.

Who are the key executives participating in VTVT's H.C. Wainwright presentation?

The presenting executives include Paul Sekhri (Chairman & CEO), Thomas Strack (CMO), Carmen Valcarce (CSO), and Michael Tung (CFO), with Emily Bodnar from H.C. Wainwright moderating.

What is vTv Therapeutics' main drug candidate?

vTv Therapeutics' main drug candidate is cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin being investigated for type 1 diabetes treatment.
Stock VTVT logo
Vtv Therapeutics

NASDAQ:VTVT

VTVT Rankings

#5393 Ranked by Market Cap
N/A Ranked by Dividends

VTVT Latest News

Aug 12, 2025
vTv Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 11, 2025
vTv Therapeutics Announces USPTO Allowance of Patent Covering Cadisegliatin
Aug 7, 2025
vTv Therapeutics Announces First Study Participant Randomized in CATT1 Phase 3 Trial of Cadisegliatin in Type 1 Diabetes
May 19, 2025
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
May 15, 2025
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update

VTVT Latest SEC Filings

Aug 12, 2025
[10-Q] vTv Therapeutics Inc. Quarterly Earnings Report
Aug 12, 2025
[8-K] vTv Therapeutics Inc. Reports Material Event

VTVT Stock Data

36.64M
1.69M
35.6%
22.05%
0.56%
Biotechnology
Pharmaceutical Preparations
United States
HIGH POINT

Related Articles

Continue reading with these related stories

View All Latest News